A PHASE I/IIa STUDY OF THE SAFETY, TOLERABILITY AND BIOLOGICAL EFFECT OF SINGLE AND REPEAT ADMINISTRATION OF THE SELECTIVELY REPLICATION-COMPETENT HERPES SIMPLEX VIRUS HSV1716 INTO THE TUMOUR-BEARING PLEURAL CAVITY (INTRAPLEURAL) IN PATIENTS WITH INOPERABLE MALIGNANT PLEURAL MESOTHELIOMA
Phase of Trial: Phase I/II
Latest Information Update: 12 Jun 2017
At a glance
- Drugs HSV 1716 (Primary)
- Indications Mesothelioma
- Focus Adverse reactions
- Sponsors Virttu Biologics
- 08 Jun 2017 Status changed from active, no longer recruiting to completed.
- 08 Sep 2016 Planned End Date changed from 1 Sep 2016 to 1 Jun 2017.
- 08 Sep 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Mar 2017.